AtriCure (NASDAQ:ATRC – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday, Wall Street Zen reports.
ATRC has been the topic of a number of other reports. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Wednesday, October 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their price objective on shares of AtriCure from $36.00 to $62.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Canaccord Genuity Group upped their price objective on shares of AtriCure from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Finally, Weiss Ratings raised shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.30.
Read Our Latest Report on ATRC
AtriCure Stock Performance
Shares of NASDAQ:ATRC opened at $56.84 on Friday. AtriCure has a 12-month low of $25.36 and a 12-month high of $66.02. The company has a market capitalization of $2.89 billion, a PE ratio of 189.47 and a beta of 1.22. The business has a 50 day moving average of $57.48 and a two-hundred day moving average of $39.17. The company has a current ratio of 4.33, a quick ratio of 3.29 and a debt-to-equity ratio of 0.17.
AtriCure (NASDAQ:ATRC – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.23. The business had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. As a group, analysts forecast that AtriCure will post 0.44 EPS for the current year.
Insider Transactions at AtriCure
In other news, insider Salvatore Privitera sold 8,404 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the completion of the transaction, the insider directly owned 134,341 shares of the company’s stock, valued at $8,732,165. This represents a 5.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Regina Groves sold 5,313 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the transaction, the director owned 34,546 shares in the company, valued at $1,873,084.12. This trade represents a 13.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 39,026 shares of company stock valued at $2,172,263 in the last three months. 4.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On AtriCure
A number of large investors have recently added to or reduced their stakes in the stock. Harbor Investment Advisory LLC purchased a new position in AtriCure during the second quarter valued at $40,000. Allworth Financial LP acquired a new stake in shares of AtriCure in the second quarter valued at about $43,000. Fulcrum Asset Management LLP acquired a new stake in shares of AtriCure in the third quarter valued at about $92,000. Integrated Wealth Concepts LLC purchased a new stake in shares of AtriCure during the second quarter worth about $46,000. Finally, Sterling Capital Management LLC increased its stake in shares of AtriCure by 841.1% during the third quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock worth $93,000 after purchasing an additional 1,472 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.
AtriCure Company Profile
AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.
Further Reading
- Five stocks we like better than AtriCure
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
